BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 10384114)

  • 1. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity.
    Curiel-Lewandrowski C; Mahnke K; Labeur M; Roters B; Schmidt W; Granstein RD; Luger TA; Schwarz T; Grabbe S
    J Immunol; 1999 Jul; 163(1):174-83. PubMed ID: 10384114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage.
    Labeur MS; Roters B; Pers B; Mehling A; Luger TA; Schwarz T; Grabbe S
    J Immunol; 1999 Jan; 162(1):168-75. PubMed ID: 9886383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-melanoma vaccinal capacity of CD11c-positive and -negative cell populations present in GM-CSF cultures derived from murine bone marrow precursors.
    Campisano S; Mac Keon S; Gazzaniga S; Ruiz MS; Traian MD; Mordoh J; Wainstok R
    Vaccine; 2013 Jan; 31(2):354-61. PubMed ID: 23146677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granulocyte-macrophage colony-stimulating factor gene transfer to dendritic cells or epidermal cells augments their antigen-presenting function including induction of anti-tumor immunity.
    Ozawa H; Ding W; Torii H; Hosoi J; Seiffert K; Campton K; Hackett NR; Topf N; Crystal RG; Granstein RD
    J Invest Dermatol; 1999 Dec; 113(6):999-1005. PubMed ID: 10594743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the functional properties of murine dendritic cells generated in vivo with Flt3 ligand, GM-CSF and Flt3 ligand plus GM-SCF.
    Daro E; Butz E; Smith J; Teepe M; Maliszewski CR; McKenna HJ
    Cytokine; 2002 Feb; 17(3):119-30. PubMed ID: 11895330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects.
    Bowne WB; Wolchok JD; Hawkins WG; Srinivasan R; Gregor P; Blachere NE; Moroi Y; Engelhorn ME; Houghton AN; Lewis JJ
    Cytokines Cell Mol Ther; 1999 Dec; 5(4):217-25. PubMed ID: 10850386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of interleukin-4 on the phenotype and function of bone marrow-derived murine dendritic cells generated under serum-free conditions.
    Wells JW; Darling D; Farzaneh F; Galea-Lauri J
    Scand J Immunol; 2005 Mar; 61(3):251-9. PubMed ID: 15787742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved immunostimulatory function of bone marrow derived macrophages transduced with the granulocyte-macrophage colony stimulating factor gene.
    Xu Z; Katsanis E
    Cancer Biother Radiopharm; 1997 Feb; 12(1):27-36. PubMed ID: 10851444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated differentiation of bone marrow-derived dendritic cells in atopic prone mice.
    Koike E; Takano H; Inoue K; Yanagisawa R
    Int Immunopharmacol; 2008 Dec; 8(13-14):1737-43. PubMed ID: 18775800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous granulocyte-macrophage colony-stimulating factor overexpression in vivo results in the long-term recruitment of a distinct dendritic cell population with enhanced immunostimulatory function.
    Miller G; Pillarisetty VG; Shah AB; Lahrs S; Xing Z; DeMatteo RP
    J Immunol; 2002 Sep; 169(6):2875-85. PubMed ID: 12218100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Matsuura I; Noguchi K; Yamaue H
    Clin Cancer Res; 2002 Aug; 8(8):2742-9. PubMed ID: 12171908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte-macrophage colony-stimulating factor gene transfer.
    Cao X; Huang X; Ju DW; Zhang W; Hamada H; Wang J
    Cancer Gene Ther; 2000 Feb; 7(2):177-86. PubMed ID: 10770625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes.
    Lu L; McCaslin D; Starzl TE; Thomson AW
    Transplantation; 1995 Dec; 60(12):1539-45. PubMed ID: 8545887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines.
    Koya RC; Kimura T; Ribas A; Rozengurt N; Lawson GW; Faure-Kumar E; Wang HJ; Herschman H; Kasahara N; Stripecke R
    Mol Ther; 2007 May; 15(5):971-80. PubMed ID: 17375074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-17 is a potent synergistic factor with GM-CSF in mice in stimulating myelopoiesis, dendritic cell expansion, proliferation, and functional enhancement.
    Liu B; Tan W; Barsoum A; Gu X; Chen K; Huang W; Ramsay A; Kolls JK; Schwarzenberger P
    Exp Hematol; 2010 Oct; 38(10):877-884.e1. PubMed ID: 20600582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8+ Tc1 responses in vivo.
    Pulendran B; Dillon S; Joseph C; Curiel T; Banchereau J; Mohamadzadeh M
    Eur J Immunol; 2004 Jan; 34(1):66-73. PubMed ID: 14971031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor vaccine therapy against recrudescent tumor using dendritic cells simultaneously transfected with tumor RNA and granulocyte macrophage colony-stimulating factor RNA.
    Naka T; Iwahashi M; Nakamura M; Ojima T; Nakamori M; Ueda K; Katsuda M; Miyazawa M; Ishida K; Yamaue H
    Cancer Sci; 2008 Feb; 99(2):407-13. PubMed ID: 18271939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.